Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

DiCE

- PMLiVE

Sanofi launches French eHealth laboratory 39BIS

The digital lab will focus on its home market and is based near Paris

dengue fever mosquito

Sanofi confirms suspected safety issue with dengue vaccine

As rival Takeda conduct phase II testing for its own dengue vaccine candidate

- PMLiVE

Reading human behaviour to create a medical future

Sanofi's Dr Anne Beal and Dr Bernard Hamelin on unlocking the doors to patient behaviour

- PMLiVE

Uptake Strategies and Sanofi win capability development prize at PMEA

Judges praised their programme’s pragmatic design and huge scalability

- PMLiVE

Sanofi’s diabetes IMPACT programme wins at PMEA 2017

Takes home first place in Excellence in Demonstrating Economic and Societal Value

Sanofi reception

Sanofi licences Principia MS drug in $805m deal

Californian biotech is set to receive $765m plus in milestone payments if PRN2246 goes to market

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

Sanofi reception

Dupixent dulls pain of diabetes slump at Sanofi

Biosimilar competition caused steep declines in its flagship product Lantus

Sanofi reception

Sanofi earmarks €170m for new French vaccines facility

Will expand its Val de Reuil production unit

Sanofi reception

US court lifts ban on sales of Sanofi’s Praluent

The duo can continue to compete against Amgen's rival PCSK9 Repatha

- PMLiVE

NICE backs Sanofi’s Kevzara for routine NHS use

Recommends the RA treatment in combination with methotrexate

Sanofi reception

Sanofi, Regeneron claim EU approval for eczema drug Dupixent

Analysts suggest the product could be worth €5bn at peak

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links